Unveiling Genetic & Proteomic Signatures for Targeted ILD/ILA Patient Selection
Time: 11:00 am
day: Day Two Track B AM
Details:
• Examining the ILD/ILA heterogeneity causing overlapping clinical features and complex differential diagnoses
• Identifying genetic and proteomic signatures to stratify patients based on their specific disease subtype
• Examining the implications on clinical trial design and endpoints of specific subgroups of ILD patients
• Balancing inclusivity to capture sufficient patient numbers with selecting the most relevant population for the targeted therapy
